Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Net Margin of 76.29% for Q1 2026, up 7542.0% year-on-year from 1.0% in Q1 2025, and down 18.96% on a QoQ basis from 64.13% in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Net Margin data on file, last reported at 76.29% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 7542.0% year-over-year to 76.29%; the trailing twelve-month figure through Mar 2026 stood at 89.56% (up 5971.0% YoY), and the FY2025 full-year result was 125.36%, up 4593.0% from the prior year.
- Net Margin for Q1 2026 stood at 76.29%, down from 64.13% in the prior quarter.
- Across five years, Net Margin topped out at 64.13% in Q4 2025 and bottomed at 211.62% in Q1 2023.
- The 5-year median for Net Margin is 148.46% (2023), against an average of 146.99%.
- The widest annual swing landed in 2022, when Net Margin surged 21773 bps; it then plunged 6266 bps in 2023.
- A 5-year view of Net Margin shows it stood at 122.9% in 2022, then tumbled by 51 bps to 185.56% in 2023, then climbed by 29 bps to 131.43% in 2024, then surged by 51 bps to 64.13% in 2025, then slipped by 19 bps to 76.29% in 2026.
- The last three Net Margin figures came in at 76.29% (Q1 2026), 64.13% (Q4 2025), and 123.64% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -76.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.29% |
| Dec 31, 2025 | -64.13% |
| Sep 30, 2025 | -123.64% |
| Jun 30, 2025 | -99.68% |
| Mar 31, 2025 | -151.71% |
| Dec 31, 2024 | -131.43% |
| Sep 30, 2024 | -196.00% |
| Jun 30, 2024 | -126.08% |
| Mar 31, 2024 | -182.70% |
| Dec 31, 2023 | -185.56% |
| Sep 30, 2023 | -148.46% |
| Jun 30, 2023 | -206.78% |
| Mar 31, 2023 | -211.62% |
| Dec 31, 2022 | -122.90% |
| Sep 30, 2022 | -129.68% |
| Jun 30, 2022 | -162.74% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -108.92% |
| Sep 30, 2021 | -347.41% |
| Jun 30, 2021 | -111.10% |
| Mar 31, 2021 | -180.14% |
| Dec 31, 2020 | -26.24% |
| Sep 30, 2020 | -124.16% |
| Jun 30, 2020 | -76.48% |
| Mar 31, 2020 | -21.74% |
| Dec 31, 2019 | 25.57% |
| Sep 30, 2019 | 17.91% |
| Jun 30, 2019 | 15.86% |
| Mar 31, 2019 | 10.46% |
| Dec 31, 2018 | 37.22% |
| Sep 30, 2018 | 40.80% |
| Jun 30, 2018 | 35.43% |
| Mar 31, 2018 | 28.50% |
| Dec 31, 2017 | 30.68% |
| Sep 30, 2017 | 96.67% |
| Jun 30, 2017 | -221.44% |
| Mar 31, 2017 | -139.77% |
| Dec 31, 2016 | -77.41% |
| Sep 30, 2016 | -26.90% |
| Jun 30, 2016 | -1.49% |
| Mar 31, 2016 | 11.22% |
| Dec 31, 2015 | 94.25% |
| Sep 30, 2015 | 17.72% |
| Jun 30, 2015 | 13.47% |
| Mar 31, 2015 | 119.91% |
| Dec 31, 2014 | 127.76% |
| Sep 30, 2014 | -191.20% |
| Jun 30, 2014 | 119.03% |
| Mar 31, 2014 | -240.88% |
| Dec 31, 2013 | -601.34% |
| Sep 30, 2013 | -329.36% |
| Jun 30, 2013 | -250.94% |
| Mar 31, 2013 | -417.47% |
| Dec 31, 2012 | 6.71% |
| Sep 30, 2012 | -23.74% |
| Jun 30, 2012 | -190.05% |
| Mar 31, 2012 | 7.19% |